The current role of BTK inhibitors in the treatment of Waldenstrom's Macroglobulinemia.

The optimal therapeutic approach for WM patients remains to be established. The question of whether a combinatory (or synergistic) regimen to overcome resistance and allow for a fixed treatment duration will allow for deep and durable response is being addressed in ongoing clinical trials.